论文信息 - Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1) - 字舞流文

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)

H. Nakagawa | M. Honma | M. Ohtsuki | S. Imafuku | Y. Tada | A. Mendelsohn | S. Sano | A. Morita | A. Igarashi | Y. Okubo | Masaki Kawamura